NewsLekha Gupta
Black Diamond Therapeutics
BDTX · NASDAQ
$2.07+$0.26 (+14.36%)TodayMarket closed ·
Prev close $1.81
Latest news
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- Press releasePRNewswire
EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight
- NewsAvi Kapoor
This PayPal Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
- NewsAvi Kapoor
US Stocks Mixed; Dollar Tree Posts Upbeat Earnings
- Press releaseGlobe Newswire
Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM
- Press releaseGlobe Newswire
Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
- Press releaseGlobe Newswire
Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
- News
Black Diamond Therapeutic Q1 EPS $0.98 Beats $0.02 Estimate, Sales $70.00M
- Press releaseGlobe Newswire
Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- NewsVandana Singh
Black Diamond Therapeutics Inks Licensing Pact With French Pharma Firm Servier For Its Early-Stage Cancer Drug Worth Over $700 Million
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- News
Market-Moving News for March 19th
- Press releaseGlobe Newswire
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
- Press releaseGlobe Newswire
Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
- Press releaseGlobe Newswire
Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway
- News
Market-Moving News for September 23rd
- Press releaseGlobe Newswire
Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations
- Press releaseGlobe Newswire
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.